Nitroprusside
Nipride, Nitroprusside (nitroprusside) is a small molecule pharmaceutical. Nitroprusside was first approved as Nitropress on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Nipride (generic drugs available since 2016-12-08, discontinued: Nitropress)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sodium nitroprusside
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NIPRIDE RTU IN SODIUM CHLORIDE 0.9% | Exela Pharma Sciences | N-209387 RX | 2017-03-08 | 2 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
100 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | 3 | 1 | 3 | 9 |
| Heart failure | D006333 | HP_0001635 | I50 | 2 | 1 | 1 | 1 | 2 | 6 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | 2 | 3 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | 1 | — | 2 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 1 | 1 | — | 2 |
| Prehypertension | D058246 | — | — | — | — | — | 1 | — | 1 |
| Hemorrhagic stroke | D000083302 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | HP_0001626 | — | 3 | 1 | — | — | 4 | 8 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 3 | — | — | — | 4 |
| St elevation myocardial infarction | D000072657 | — | — | — | 1 | — | — | 2 | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | 1 | 2 |
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | 1 | 2 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | 1 | — | — | — | 1 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vasodilation | D014664 | — | — | 5 | — | — | — | 5 | 10 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | 6 | 9 |
| Vasoconstriction | D014661 | — | — | 4 | — | — | — | 2 | 6 |
| Heart disease risk factors | D000082742 | — | — | 3 | — | — | — | — | 3 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | 2 | — | — | — | — | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | — | — | — | — | 2 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 1 | — | — | — | 1 | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | — | — | 1 |
| Vascular stiffness | D059289 | — | — | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 4 | 4 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 2 | 2 |
| Cerebral hemorrhage | D002543 | — | — | — | — | — | — | 2 | 2 |
| Microcirculation | D008833 | — | — | — | — | — | — | 2 | 2 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Fabry disease | D000795 | Orphanet_324 | E75.21 | — | — | — | — | 1 | 1 |
| Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | — | — | — | — | 1 | 1 |
| Hemangioendothelioma | D006390 | — | — | — | — | — | — | 1 | 1 |
| Anesthesia | D000758 | — | — | — | — | — | — | 1 | 1 |
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nitroprusside |
| INN | — |
| Description | Sodium nitroprusside (SNP), sold under the brand name Nitropress among others, is a medication used to lower blood pressure. This may be done if the blood pressure is very high and resulting in symptoms, in certain types of heart failure, and during surgery to decrease bleeding. It is used by continuous injection into a vein. Onset is typically immediate and effects last for up to ten minutes.
|
| Classification | Small molecule |
| Drug class | atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 13755-38-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2097081 |
| ChEBI ID | 7596 |
| PubChem CID | 11953895 |
| DrugBank | DB00325 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 21,888 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
156 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use